Results 231 to 240 of about 34,329 (314)

Clinical implications of PD‐L1 expression in oncogene‐driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors

open access: yesInternational Journal of Cancer, Volume 159, Issue 1, Page 269-279, 1 July 2026.
What's New? PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in patients with non‐small‐cell lung cancer lacking oncogenic driver mutations. However, its significance in patients with driver mutations remains unclear. In this study of 273 patients with stage IV non–‐small‐cell lung cancer harboring diverse driver alterations and PD ...
Xiaoxiao Fan   +7 more
wiley   +1 more source

Prognostic Role of CA19-9 in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. [PDF]

open access: yesCancers (Basel)
Masuda T   +7 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

open access: yesInternational Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang   +5 more
wiley   +1 more source

Hydrogel‐based drug delivery systems for intracerebral hemorrhage with therapeutic advances and emerging roles of the bone–brain axis

open access: yesInterdisciplinary Medicine, Volume 4, Issue 4, July 2026.
Hydrogel‐based drug delivery systems offer a promising approach for treating intracerebral hemorrhage (ICH) by overcoming blood‐brain barrier limitations, enabling precise, sustained release of neuroprotective and anti‐inflammatory agents. These systems enhance treatment efficacy, but challenges remain in biosafety, drug penetration, and scalability ...
Haojun Shi   +18 more
wiley   +1 more source

Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen   +9 more
wiley   +1 more source

A Nomogram for Phosphate Buffers

open access: yesJournal of Biological Chemistry, 1965
openaire   +2 more sources

Surgical Management of Recurrent Retroperitoneal Sarcomas: Experience From a High‐Volume Sarcoma Centre

open access: yesJournal of Surgical Oncology, Volume 134, Issue 1, Page 116-127, July 2026.
ABSTRACT Background Retroperitoneal sarcoma (RPS) is a rare and complex malignancy, requiring specialized multidisciplinary care. While a significant progress has been made in managing a primary RPS, there is a limited literature on the outcomes of recurrent RPS (RecRPS).
Abdeali Saif Arif Kaderi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy